Net Deals Web Search

Search results

1. Results From The WOW.Com Content Network

2. File:Novartis-Logo.svg - Wikipedia

   en.wikipedia.org/wiki/File:Novartis-Logo.svg

   File:Novartis-Logo.svg. Size of this PNG preview of this SVG file: 512 × 84 pixels. Other resolutions: 320 × 53 pixels | 640 × 105 pixels | 1,024 × 168 pixels | 1,280 × 210 pixels | 2,560 × 420 pixels. Original file ‎ (SVG file, nominally 512 × 84 pixels, file size: 2 KB) This is a file from the Wikimedia Commons.

3. Novartis - Wikipedia

   en.wikipedia.org/wiki/Novartis

   Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...

4. Sandoz - Wikipedia

   en.wikipedia.org/wiki/Sandoz

   Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. [4] Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until ...

5. Chiron Corporation - Wikipedia

   en.wikipedia.org/wiki/Chiron_Corporation

   Chiron Corporation ( / ˈkaɪrɒn / KY-ron) [1] was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006. It had offices and facilities in eighteen countries on five continents. Chiron's business and research was in three main areas: biopharmaceuticals ...

6. Tisagenlecleucel - Wikipedia

   en.wikipedia.org/wiki/Tisagenlecleucel

   Tisagenlecleucel, sold under the brand name Kymriah, is a CAR T cells medication for the treatment of B-cell acute lymphoblastic leukemia (ALL) which uses the body's own T cells to fight cancer ( adoptive cell transfer ). [9] [7]

7. Novartis in advanced talks to buy Cytokinetics- source - AOL

   www.aol.com/news/novartis-advanced-talks-buy...

   (Reuters) -Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.